Eight patients with infection due to human immunodeficiency virus type 1 developed fat pads at the bases of their necks a median of 22 weeks (range, 4 -61 weeks) after initiation of protease inhibitor therapy. This finding was seen in association with the use of each of the available protease inhibitors. The patients had no other cushingoid features or histories of corticosteroid use, and all had normal 24-hour urine cortisol levels. The computed tomography scans of five patients showed large, nonencapsulated accumulations of subcutaneous adipose tissue. Histological examination of tissue from one patient confirmed a nonlipomatous subcutaneous fat deposition. Although the pathogenesis of this unique clinical finding is unclear, the temporal relationship between the use of protease inhibitors and the development of cervical fat pads is suggestive of a complication of therapy.
HIV-1 protease, an aspartyl protease, is an essential enzyme proximately one-half of whom are receiving at least one protease inhibitor. Between May 1996 and September 1997, eight for the proteolytic cleavage of precursor proteins in the final step of viral maturation. Inhibition of this enzyme prevents the patients presented with progressively enlarging soft tissue masses at the base of the neck (figure 1). Three patients comrelease of mature virions from infected host cells [1] . The use of protease inhibitor -based antiretroviral regimens has been plained of associated warmth, discomfort, and restriction of neck movement; the remainder were asymptomatic but exshown to increase CD4 / T cell counts [2 -7] , reduce plasma HIV RNA levels [2 -7] , slow the progression of HIV-1 infecpressed cosmetic concerns. All patients were receiving at least one of the protease inhibitors saquinavir, ritonavir, indinavir, tion to AIDS [6, 8] , and decrease mortality [6, 8] . Although mild adverse effects are commonly reported, protease inhibitors or nelfinavir, and all but patient 8 (table 1) were also receiving reverse transcriptase inhibitors. None of the patients were takappear generally safe and well tolerated [1, 9] . However, follow-up periods in clinical trials thus far have been relatively ing exogenous corticosteroids, growth hormone, or megestrol acetate. Patient 1 was receiving intramuscular injections of short, and little is known about the long-term side effects of these drugs. For instance, increased experience with indinavir depotestosterone and decadurabolin every 2 weeks, and patient 6 was receiving exogenous estrogen as hormonal replacement has led to reports of nephrolithiasis [10, 11] , uveitis [12] , hepatitis [13, 14] , and hyperbilirubinemia [15] . Hyperlipidemia has therapy. been attributed to the use of ritonavir [16] , and all the available The length of time between the initiation of protease inhibitor protease inhibitors have been associated with the development therapy and the onset of a clinically apparent neck mass varied of hyperglycemia [17] . from 4 weeks to 61 weeks (median length of time, 22 weeks). We report the development of cervical fat pads in eight On physical examination, the soft tissue masses resembled the patients receiving protease inhibitor therapy.
''buffalo hump'' characteristic of hypercortisolism. Patients 3 and 7 also had supraclavicular fullness, and patient 3 had See editorial response by Hirsch and Klibanski submandibular soft-tissue swelling. All patients were normoon pages 73 -5.
tensive and had no postural changes in blood pressure. Of note, six patients gained weight following the initiation of protease inhibitor therapy (median weight gain, 3.5 kg; mean [{SD] Cases weight gain, 3.14 { 2.90 kg; n Å 8). Truncal obesity was not evident in any patient, and cushingoid features were otherwise Staff at the Immunodeficiency Clinic of the Ottawa General absent. Hospital (Ottawa) follow up ú800 HIV-positive patients, apLaboratory investigations for all patients included levels of serum electrolytes, glucose, and triglycerides. A 24-hour urine cortisol measurement was done for all patients except patient navir plus saquinavir (patient 8) had random triglyceride levels Patient 5 chose to discontinue all antiretroviral therapy because of progressive enlargement of his neck mass. Ten greater than twice the upper limit of normal. Five patients had CT scans that showed subcutaneous accumulations of homogeweeks after stopping therapy, there has been no objective evidence of regression of the mass. In the remaining patients neous fat tissue in the midline at the base of the neck overlying the trapezius muscle, with no evidence of inflammation in the there has been no further progression in the size of the cervical masses. adjacent tissues.
The mass was removed from patient 1 for diagnostic and cosmetic purposes. Intraoperatively, it was highly vascular and Discussion firmly adherent to surrounding tissues. In contrast to lipomas, which characteristically shell out easily, removal of this lesion
The development of cervical fat pads in HIV-1-infected patients receiving antiretroviral therapy appears to be a novel was difficult. Gross pathological examination revealed several fragments of unremarkable adipose tissue with a few septae.
observation. The temporal relationship between the use of protease inhibitors and the onset of this unusual finding in The microscopic appearance was consistent with nonencapsulated mature fat tissue (figure 2). This patient continues to take our patients is suggestive of a side effect of therapy. The development of the cervical neck masses appeared to be indenelfinavir and saquinavir, with no recurrence of his neck mass at 10 months after excision. pendent of the protease inhibitors used, the immunologic Table 1 . Demographic, clinical, and laboratory data obtained before the initiation of protease inhibitor therapy and at the onset of cervical fat pads in HIV-1-infected patients. 
